The application of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) in CKD patients leads to partial relief of oxidative stress in the kidney [7], and the effects of antioxidant interventions targeting the level of total cellular redox status are disappointing, since traditional antioxidants are not well taken up by mitochondria. Here, ACE is linked to chronic kidney disease.